stockrow
Friday 6 November 2026
Export ABVX’s income statement to Excel — free account
Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
86.19
2.01
+2.39%
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) Net income
Abivax SA Sponsored ADR's net income for fiscal 2025 was −$380.3M, compared with −$190.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$458.7M. Over the past ten years it has ranged from −$380.3M (fiscal 2025) to −$18.7M (fiscal 2018) — the current reading is the lowest in ten years. Net income has fallen for 7 consecutive fiscal years. Abivax SA Sponsored ADR ranks 584th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$380.3M | — |
| FY2024 | −$190.7M | — |
| FY2023 | −$159.9M | — |
| FY2022 | −$64.0M | — |
| FY2021 | −$48.9M | — |
| FY2020 | −$42.8M | — |
| FY2019 | −$34.3M | — |
| FY2018 | −$18.7M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$136.2M | — |
| Mar 2026 | −$56.7M | — |
| Dec 2025 | −$83.2M | — |
| Sep 2025 | −$182.7M | — |
| 10 more quarters | Free account |
Against its own ten years
Low −$380.3M
High −$18.7M
Ten-year median
−$56.4M
Current reading's percentile
13
Net income against peers
| Company | Net income |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | $162.3M |
| ORKA Oruka Therapeutics, Inc. compare | −$132.9M |
| AXSM Axsome Therapeutics, Inc. compare | −$157.3M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −$193.8M |
| SYRE Spyre Therapeutics, Inc. compare | −$263.9M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$272.1M |
| PRAX Praxis Precision Medicines, Inc. compare | −$339.1M |
| ABVX Abivax SA Sponsored ADR | −$458.7M |
| CYTK Cytokinetics, Incorporated compare | −$777.9M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item